ow-Dose Hormone Therapy Initiated early after Menopause and Changes in Artery Wall Composition (AWC), as Assesssed by High-Frequency Ultrasound. - AWC LowE

ppsala University Hospital0 个研究点开始时间: 2009年6月30日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Postmenopausal women, i.e. > 1 year after last menstrual period
•Age 50 - 59 years; Having an intact uterus; HRT naive or more than 3 yrs since last use of medium potent HRT (low-dose vaginal regimens allowed); Endometrial thickness <=5mm at inclusion. Normal mammogram within the last 12 months.
•Signed informed consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Current or previous use of HT within the last 3 years; current use of lipid-lowering agents, oral corticosteroids for more than one month within the last 3 years;Body Mass Index (BMI) >35 kg/m2;
•Known or suspected past or present history of breast cancer;
•Known, suspected or past estrogen dependent neoplasia, e.g. endometrial cancer;
•Known, present or past history of coronary heart disease.
•Contraindication for HT: undiagnosed genital bleeding, untreated endometrial hyperplasia, previous idiopathic or current venous thromboembolism (deep venous thrombosis, pulmonary embolism), active or recent arterial thromboembolic disease ) e.g. angina, myocardial infarction), acute liver disease, or a history of liver disease as long as liver function tests have failed to return to normal, known hypersensitivity to the active substances or to any of the excipients, porphyria
•Hypertension: >150/95
•Untreated Thyroid disease.

发起方

ppsala University Hospital